


3/22/04

10/05, 885

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)							ATTY. DOCKET NO. PC25078A		SERIAL NO. To be assigned						
							APPLICANT John W. Benbow, et al.		FILING DATE Concurrently herewith			GROUP 1624			
							FILING DATE Concurrently herewith					GROUP To be assigned			
U.S. PATENT DOCUMENTS															
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
US		0	1	0	3	1	8	5	08/01/02	Sanner et al.	A61K	31/55			
FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
												YES	NO		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
ZT			Singh, P. et al., Indian Journal of Chemistry, Vol. 35B, pp. 929-934, September 1996, "Fujita-Ban and Hansch analyses of A ₁ - and A ₂ -adenosine receptor binding affinities of some 4-amino[1,2,4]triazolo[4,3- α]quinoxalines."												
ZT			Sarges, R. et al., J. Med. Chem., Vol. 33, pp. 2240-2254, 1990, "4-Amino[1,2,4]triazolo[4,3- α]quinoxalines. A Novel Class of Potent Adenosine Receptor Antagonists and Potential Rapid-Onset Antidepressants."												
ZT			Adenot, M. et al., Eur J Med Chem, Vol. 32, pp. 493-504, 1997, "Interest of cluster significance analysis in structure-affinity relationships for non-xanthine heterocyclic antagonists of adenosine."												
ZT			Colotta, V. et al., Arch. Pharm. Pharm. Med. Chem., Vol. 332, pp. 39-41, 1994, "4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo[4,3- α]quinoxalin-1-one: A New A _{2A} Adenosine Receptor Antagonist with High Selectivity versus A1 Receptors." (1999)												
ZT			Colotta, V. et al., J. Med. Chem., Vol. 43, pp. 1158-1164, 2000, "1,2,4-Triazolo[4,3- α]quinoxalin-1-one: A Versatile Tool for the Synthesis of Potent and Selective Adenosine Receptor Antagonists."												
EXAMINER	<i>Zach J</i>							DATE CONSIDERED			21 FEBRUARY 2006				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															



INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>			ATTY. DOCKET NO. PC25078A				SERIAL NO. 10/805,885							
			APPLICANT John W. Benbow et al.				GROUP 1614 1624							
			FILING DATE 03/22/04											
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	US	02	1	6	5	1	0	7	11.07.02	Fishman et al.	514	46		
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO
ZT	EP	1	0	5	0	5	3	5	08.11.00	EP	C07D	487/04		
ZT	WO	02	0	8	3	1	4	0	24.10.02	International	A61K	31/5025		
ZT	EP	1	2	9	5	8	8	5	26.03.03	EP	C07D	487/04		
ZT	WO	0	2	5	0	0	7	9	27.06.02	International	C07D	487/04		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
ZT			Smith, David et al., 3-Anilino-4-arylmaleimides: Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 (GSK-3), Pergamon Bioorganic & Medicinal Chemistry Letters 11 (2001) pp. 635-639.											
ZT			Bertrand, J.A., et al., Structural Characterization of the GSK-3B Active Site Using Selective and Non-selective ATP-mimetic Inhibitors, J.Mol.Biol. (2003) 333, 393-407.											
EXAMINER <u>Zulma</u>			DATE CONSIDERED 21 FEBRUARY 2006											
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>														

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE